CCCC(CCCC)
CCCC
ANALYST COVERAGE14 analysts
BUY
▲ +98.9%upside to target
Key MetricsTTM
Market Cap$291.55M
Revenue TTM—
Net Income TTM—
Free Cash Flow—
Gross Margin94.8%
Operating Margin-326.6%
Net Margin-297.8%
Return on Equity-50.7%
Return on Assets-31.6%
Debt / Equity—
Current Ratio9.00
EPS TTM—
PRICE
Prev Close
3.28
Open
3.23
Day Range3.19 – 3.55
3.19
3.55
52W Range1.21 – 3.95
1.21
3.95
84% of range
VOLUME & SIZE
Avg Volume
3.1M
FUNDAMENTALS
P/E Ratio
-3.2x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
2.05
High vol
TECHNICAL
RSI (14)
54
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 116 days
Sep 15
CCCC News
About
C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.
Sector
Industry
Biological Product (except Diagnostic) Manufacturing
Website
Paige MahaneyChief Scientific Officer
Christopher NasveschukSenior Vice President of Chemistry
Nathanael S. GrayCo-Founder & Member of Scientific Advisory Board
Andrew J. HirschChief Executive Officer, President & Director
Mark MosslerChief Accounting Officer
Kendra AdamsChief Financial Officer and Head of Corporate Affairs & Treasurer
Courtney SolbergSenior Manager of Investor Relations
Kelly SchickChief People Officer
Isabel ChiuSenior Vice President of Strategic Alliances & Business Development
Kenneth C. AndersonCo-Founder, Independent Director & Member of Scientific Advisory Board
Leonard J. ReynoChief Medical Officer